Suchergebnisse - "Curtin, Nicola"

PubPharm (11)

1

Targeting the DNA damage response for cancer therapy

enthalten in: Biochemical Society transactions | 2023

von Curtin, N.

2

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells

enthalten in: Cancers | 2021

von King, D. | Southgate, H. | Roetschke, S. | +10

3

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting

enthalten in: Cancers | 2020

von Bradbury, A. | O'Donnell, R. | Drew, Y. | +2

4

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells

enthalten in: Cancers | 2020

von Smith, H. | Prendergast, L. | Curtin, N.

5

The Development of Rucaparib/Rubraca® : A Story of the Synergy Between Science and Serendipity

enthalten in: Cancers | 2020

von Curtin, N.

6

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

enthalten in: Frontiers in oncology | 2020

von Southgate, H. | Chen, L. | Curtin, N. | +1

7

The Use of PARP Inhibitors in Cancer Therapy : Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Shall, S. | Gaymes, T. | Farzaneh, F. | +2

8

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13

9

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

10

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10